

**Supplemental Table 1.** Plasma tenofovir (TFV) pharmacokinetics

	<b>C<sub>tau</sub></b> <b>(ng/mL)</b>	<b>C<sub>max</sub></b> <b>(ng/mL)</b>	<b>T<sub>max</sub></b> <b>(hrs)</b>	<b>AUC<sub>tau</sub></b> <b>(ng*hr/mL)</b>	<b>T<sub>1/2</sub></b> <b>(hrs)</b>
<b>OVERALL</b>	<b>58.7</b> <b>(52.8, 65.3)</b>	<b>304.4</b> <b>(276.4, 335.3)</b>	<b>1.2</b> <b>(1.1, 1.3)</b>	<b>2740</b> <b>(2503, 2999)</b>	<b>15.9</b> <b>(15.0, 17.0)</b>
Transgender women (N=26)	56.3 (47.0, 67.3)	313.7 (278.6, 353.1)	1.2 (1.0, 1.4)	2660 (2314, 3057)	16.0 (14.3, 17.9)
Transgender men (N=24)	61.5 (54.8, 69.1)	294.7 (250.1, 347.4)	1.2 (1.0, 1.4)	2829 (2502, 3199)	15.9 (14.9, 16.9)
TM vs. TW, GMR (95% CI)	1.09 (0.88, 1.35)	0.93 (0.77, 1.14)	1.03 (0.84, 1.28)	1.06 (0.89, 1.28)	0.99 (0.88, 1.13)
P-value	0.401	0.524	0.750	0.499	0.931
<b><i>HISTORICAL CONTROLS</i></b>					
Hiransuthikal, et al. GM (CV%)	59.8 (29.6)	311.4 (30.0)	-	2530 (31.3)	-
Shieh, et al. Median (IQR)	60 (55, 76)	349 (269, 398)	-	3431 (2720, 3649)	-
Cirincione, et al. GM (90% CI)	-	280 (260, 310)	2.2 (1.8, 2.8)	2760 (2570, 2960)	15.5 (12.9, 18.6)
Cell-PrEP <sup>a</sup> Mean (95% CI)	-	-	-	2424 (2112, 2736)	19.0 (15, 22)

All values expressed as geometric mean (95% CI), unless otherwise stated. <sup>a</sup> AUC calculated as C<sub>ss</sub>\*24 hrs.